TP53 DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification

Gaia Martire; Federica Lovisa; Elisa Carraro; Domenico Rizzato; Simone Cesaro; Rosa Maria Mura; Annalisa Tondo; Cinzia Bertolin; Francesca Boaretto; Leonardo Salviati; Alessandra Biffi; Marta Pillon; Lara Mussolin

doi:10.3324/haematol.2023.284868

TP53 DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification

Haematologica. 2024 Sep 1;109(9):3031-3036. doi: 10.3324/haematol.2023.284868.

Authors

Affiliations

¹ Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova.
² Istituto di Ricerca Pediatrica Città della Speranza, Padova.
³ Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova.
⁴ Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona.
⁵ Paediatric Hematology and Oncology Unit, Ospedale Pediatrico Microcitemico, Cagliari.
⁶ Department of Hematology-Oncology, Anna Meyer Children's Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Firenze.
⁷ Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Clinical Genetics Unit, Department of Women's and Children's Health, University of Padova, Padova.
⁸ Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Burkitt Lymphoma* / diagnosis
Burkitt Lymphoma* / drug therapy
Burkitt Lymphoma* / genetics
Burkitt Lymphoma* / mortality
Child
Child, Preschool
Female
Humans
Male
Mutation*
Prognosis
Rituximab* / therapeutic use
Tumor Suppressor Protein p53* / genetics

Substances

Rituximab
Tumor Suppressor Protein p53
TP53 protein, human

Grants and funding

Funding: This work was supported by Fondazione Città della Speranza, Padova, Italy (Grant 21/03 to LM); AIRC, Milano, Italy (Investigator Grant - IG 2018 #21385 to LM). This work was also supported by the Comitato Assistenza Socio-Sanitaria in Oncoematologia Pediatrica (CASOP), Padova, Italy, and the Associazione Italiana contro le Leucemie-Linfomi e Mieloma (AIL), Rovigo, Italy